Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

19 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Epzicom Articles

Mylan gets tentative FDA approval for generic Epzicom

23 February 2012

Teva gets BDP allergy drug NDA accepted by FDA; sued by ViiV over Epzicom

9 August 2011

GlaxoSmithKline to refocus some research and seek efficiencies, despite posting huge 4th-qtr 2009 profits rise; applause from Science Minister

5 February 2010

ViiV Healthcare launches: a new specialist HIV company for GSK and Pfizer

4 November 2009

GSK's Epzicom comparable to Truvada

18 August 2008

Stock Commentary - New York week to March 3, 2008

10 March 2008

Small number of combination drugs reaching the Japanese market

24 September 2007

Increasing HIV survival rates present new treatment challenges; Datamonitor report

4 October 2004

US FDA near-term priorities: innovation, access, cGMPs, consumer protection

9 August 2004

GSK's combi-HIV drug Epzicom OKed by FDA

9 August 2004

Showing 1-10 of 10 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Encouraging results with Sangamo's SB-728-T in HIV treatment
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
  • Neovacs moving forward in rheumatoid arthritis, say analysts
  • Encouraging results with Sangamo's SB-728-T in HIV treatment
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
  • Neovacs moving forward in rheumatoid arthritis, say analysts

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS